Overview of the current status of gene therapy for primary immune deficiencies (PIDs).

Abstract

Over 3 decades, gene therapy has advanced from a logical idea to becoming a clinical reality for several of the most severe primary immune deficiencies, as well as other inherited disorders. The first gene therapy medicines have been licensed for marketing and several more are advancing toward that goal to make them widely available, beyond clinical trials. Although common platforms of cells, vectors, or editing reagents are used for these disorders, each individual genetic cause of an immune deficiency requires its own vector or editing tools and a package of preclinical data on efficacy and safety to initiate clinical trials. One-by-one, gene therapy for primary immune deficiencies is being brought to the clinic and hopefully will provide safe and effective therapies.

• Authors: Caroline Y Kuo, Donald B Kohn
• Journal: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 146 Issue 2 Pg. 229-233 (08 2020) ISSN: 1097-6825 [Electronic] United States
• PMID: 32771134 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Topics

• Animals
• Gene Editing
• Genetic Therapy (methods, trends)
• Genetic Vectors
• Hematopoietic Stem Cell Transplantation
• Humans
• Primary Immunodeficiency Diseases (therapy)